Background: This study investigated the prognostic relevance of the Controlling Nutritional Status (CONUT) score and the Aggregate Index of Systemic Inflammation (AISI) for predicting all-cause mortality (ACM) in patients undergoing maintenance hemodialysis (MHD). Furthermore, the study aimed to identify independent prognostic indicators to aid clinical risk categorization and tailored therapeutic interventions. Methods: A retrospective cohort study was performed with a follow-up duration of 5 years. Extensive demographic data and clinical laboratory results were gathered, and patients were followed until December 2024, with ACM set as the principal endpoint. The predictive capabilities of the CONUT score and AISI for ACM among MHD patients were evaluated by receiver operating characteristic (ROC) curve analysis. Survival outcomes were depicted through Kaplan–Meier curves, and Cox proportional hazards regression was utilized to ascertain significant prognostic factors for five-year ACM. Results: In total, 614 patients on MHD were enrolled. ROC analysis yielded areas under the curve (AUC) of 0.704 for the CONUT score and 0.694 for AISI, with optimal threshold values identified at 3.5 and 306.100, respectively. Patients exhibiting AISI below 306.100 had markedly better cumulative survival rates ( χ2 = 48.085, p < 0.001). Similarly, patients with CONUT scores equal to or greater than 3.5 displayed significantly reduced cumulative survival compared to those scoring below 3.5 ( χ2 = 65.147, p < 0.001). Multivariate Cox regression analyses demonstrated that central venous catheter (CVC) utilization, CONUT score ≥ 3.5, AISI ≥ 306.100, and elevated aspartate aminotransferase (AST) levels were independently associated with increased five-year ACM ( p < 0.05). Conversely, being female and exhibiting elevated concentrations of hemoglobin (HGB), urea, and creatinine were protective against mortality ( p < 0.05). Conclusion: Both AISI and the CONUT score provide significant prognostic information for predicting ACM in patients undergoing MHD. Their combined use constitutes a robust, accessible tool for identifying high-risk individuals in this population.
24 February 2025 in Journal of International Medical Research
Nephrotic syndrome can occur secondary to malignancy, and its resolution is sometimes observed following tumor resection. We herein report the case of a 67-year-old Asian man who presented with membranous nephropathy associated with carcinoma of the ampulla of Vater. The patient initially presented with edema, hypoalbuminemia, and significant proteinuria with positive PLA2R antibody. Following surgical removal of the tumor, his urinary protein levels normalized, his serum albumin returned to normal, and the nephrotic syndrome achieved complete remission. This case underscores the importance of screening for secondary causes, such as malignancies, in patients with nephrotic syndrome. For those with malignancy-associated nephrotic syndrome, prompt and targeted treatment of the underlying tumor is critical to avoid missing the window for surgical intervention. This report aims to provide insights into the diagnosis and management of tumor-associated nephrotic syndrome, contributing to a better understanding of this rare clinical entity.
25 May 2025 in Journal of International Medical Research
Objective: This study aimed to evaluate the effect of surgical versus nonsurgical treatment on mortality in patients with encapsulating peritoneal sclerosis who underwent peritoneal dialysis. Methods: A comprehensive search using PubMed, Google Scholar, MEDLINE, Science Direct, Scopus, and CNKI databases was conducted to extract relevant data based on predefined inclusion criteria. RevMan5.2 was applied to analyze and compare the effect of surgical versus nonsurgical treatment on mortality in patients with encapsulating peritoneal sclerosis who underwent peritoneal dialysis. Results: A total of 7 studies involving 70 surgical and 57 nonsurgical patients were included, with 61.4% females and 38.6% males. Among them, 69 were Asian and 58 were European patients, with 37.7% and 75.9% of Asian and European patients accepting surgical treatment, respectively. Pooled data analysis indicated that surgical treatment was associated with significantly lower mortality than nonsurgical treatment in patients with encapsulating peritoneal sclerosis (odds ratio = 0.25, 95% confidence interval: 0.11–0.57, Z = 3.29; P = 0.001). Subgroup analysis revealed that Asian patients who accepted surgical treatment had significantly lower mortality than those receiving nonsurgical treatment (odds ratio = 0.19, 95% confidence interval: 0.06–0.57, Z = 2.93; P = 0.003), whereas no significant difference was observed in mortality between surgical and nonsurgical treatments in European patients (odds ratio = 0.38, 95% confidence interval: 0.10–1.41, Z = 1.45; P = 0.15). Conclusions: Surgical treatment was associated with reduced mortality in patients with encapsulating peritoneal sclerosis compared with nonsurgical treatment; however, this benefit was more significant in Asian patients than in European patients.